Clinical Trial Update: A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update comparing [177Lu]Lu-PSMA-617 to a change in androgen receptor-directed therapy for taxane-treatment naive Chinese men with progr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Androgen receptor-directed therapy (unspecified)
• [177Lu]Lu-PSMA-617 (lutetium-177 labeled PSMA-617)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Status: ACTIVE_NOT_RECRUITING